Fractyl Health (NASDAQ: GUTS) is emerging as one of the most interesting names in the metabolic space thanks to its flagship device Revita®, a duodenal mucosal resurfacing (DMR) procedure designed to maintain weight loss after stopping GLP-1 drugs.